The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The companies aim to expand treatment options for millions living with metabolic disorders
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Subscribe To Our Newsletter & Stay Updated
